Company intelligence / Profile preview
Recombinant Technologies
Cheshire, Connecticut, United Statesrecombtech.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Successful proof-of-concept studies for AmyTrap drug candidates have shown ability to trap and clear Alzheimer's disease-causing Aβ-amyloid plaques, restoring memory by returning the natural balance of beta-amyloid in the body. The company has received Phase II SBIR grant from NIH to further develop AmyTrap for Alzheimer's treatment[7].
- Therapeutic areas
- Neurology
- Modalities
- Small moleculespeptides
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Health ConnexionsSA Capital Partners LLC
Beyond the preview
Go deeper on Recombinant Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recombinant Technologies.